Johnson & Johnson Gmbh

Johnson & Johnson Products, Inc.

David T Rovee

James A Mezick

John R Marvel

Robert J Gander

Cary B Linsky

Wilson Nashed

A pharmaceutical composition for topical treatment of cutaneous disorders or disruptions characterized by skin inflammation or hyperproliferative epidermal activity comprises the combination of a topically active anti-inflammatory corticosteroid and a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the hydratropic acid derivatives; acetylsalicylic acid; the pyrazolon derivatives; the fenamic acid derivatives; the aroyl-substituted pyrroles and the substituted arylacetohydroxamic acids in a pharmaceutically acceptable topical vehicle. Treatment of above cutaneous disorders may also be effected by concurrent therapy using separate applications of corticosteroid and non-steroid.

Topical anti-inflammatory drug therapy

A pharmaceutical composition for topical treatment of cutaneous disorders or disruptions characterized by skin inflammation or hyperproliferative epidermal activity comprises the combination of a topically active anti-inflammatory corticosteroid and a non-steroidal anti-inflammatory agent which is an inhibitor of prostaglandin synthetase selected from the group consisting of the hydratropic acid derivatives; acetylsalicylic acid; the pyrazolone derivatives; the fenamic acid derivatives; the aroyl-substituted pyrroles and the substituted arylacetohydroxamic acids in a pharmaceutically acceptable topical vehicle. Treatment of above cutaneous disorders may also be effected by concurrent therapy using separate applications of corticosteroid and non-steroid.

Treatment of inflammation by applying topically a selected acylaminophenol in a pharmaceutically acceptable topical vehicle.

Topical acylaminophenols

A non-occlusive, non-adherent dressing for wounds, the dressing comprising an imperforate (i.e. continuous) flexible film for contacting the wound, and an absorbent pad backing the wound-contacting film and extending beyond a substantial portion of the periphery of the film, the dressing having vapor transport cavity approximating that of intact human skin. The absorbent pad removes wound exudate from the proximate area of the wound without the pad coming into contact with the open wound itself. The final construction, comprising the film and absorbent backing, permits a measurable amount of moisture vapor to be transmitted (greater than 0.06 mg/cm.sup.2 /hr), thereby greatly reducing the degree of maceration and other problems that may be produced by a fully occlusive dressing.

Growing community of inventors

Somerset, NJ, United States of America

David T Rovee